Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has shared an update.
On October 13, 2025, BlackRock, Inc., a major shareholder, adjusted its voting rights in Smith & Nephew plc, resulting in a new total of 7.17% of voting rights. This change, notified on October 14, 2025, reflects a slight increase from the previous total of 6.76%, indicating a strategic adjustment in BlackRock’s investment in the company. The adjustment in voting rights could influence Smith & Nephew’s governance and strategic decisions, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SNN) stock is a Hold with a $37.50 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats shows strong financial performance with robust revenue and profit growth, which is the most significant factor in its stock score. The earnings call provided positive insights into future growth, despite some challenges in emerging markets and potential tariff impacts. The technical analysis indicates weak momentum, and the stock’s valuation is relatively high, which slightly offsets the overall positive outlook.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based company operating in the medical technology industry, primarily known for its advanced wound management, orthopedics, and sports medicine products. The company focuses on providing innovative solutions to improve patient outcomes and enhance healthcare delivery.
Average Trading Volume: 786,498
Technical Sentiment Signal: Buy
Current Market Cap: $14.98B
For an in-depth examination of SNN stock, go to TipRanks’ Overview page.